(Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists

Journal of Medicinal Chemistry

Volumn 51, Issue 8, 2008, Pages 2522-2532

  Volk, Balázs ^a   Barkóczy, József ^a   Hegedus, Endre ^a   Udvari, Szaboles ^a   Gacsályi, István ^a   Mezei, Tibor ^a   Pallagi, Katalin ^a   Kompagne, Hajnalka ^a   Lévay, György ^a   Egyed, András ^a   Hársing Jr , Lásló G ^a   Spedding, Michael ^b   Simig, Gyula ^a  

^a EGIS PHARMACEUTICALS LTD   (Hungary)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

(PHENYLPIPERAZINYL BUTYL)OXINDOLE; 1 PHENYLPIPERAZINE DERIVATIVE; 3 [4 (6,7 DIHYDRO 4H THIENO[3,2 C]PYRIDIN 5 YL)BUTYL] 3 ETHYL 1,3 DIHYDRO 2H INDOL 2 ONE; 3 [4 [4 (3 CHLOROPHENYL) PIPERAZIN 1 YL]BUTYL] 3 ETHYL 6 FLUORO 1,3 DIHYDRO 2H INDOL 2 ONE; 3 [4 [4 (3 CHLOROPHENYL) PIPERAZIN 1 YL]BUTYL] 3 ISOBUTYL 1,3 DIHYDRO 2H INDOL 2 ONE; 3 [4 [4 (4 CHLOROPHENYL) PIPERAZIN 1 YL]BUTYL] 1,3 DIHYDRO 2H INDOL 2 ONE; 3 [4 [4 (4 CHLOROPHENYL) PIPERAZIN 1 YL]BUTYL] 3 ETHYL 1,3 DIHYDRO 2H INDOL 2 ONE; 3 [4 [4 (4 CHLOROPHENYL) PIPERAZIN 1 YL]BUTYL] 3 ETHYL 6 FLUORO 1,3 DIHYDRO 2H INDOL 2 ONE; 3 [4 [4 (PHENYLPIPERAZIN 1 YL)BUTYL] 3 ETHYL 1,3 DIHYDRO 2H INDOL 2 ONE OXALATE; 3 [5 [4 (3 CHLOROPHENYL) PIPERAZIN 1 YL]PENTYL] 3 ETHYL 1,3 DIHYDRO 2H INDOL 2 ONE OXALATE; 3 [5 [4 (4 CHLOROPHENYL) PIPERAZIN 1 YL]PENTYL] 3 ETHYL 1,3 DIHYDRO 2H INDOL 2 ONE; 3 ETHYL 3 [4 [4 (2 METHOXYPHENYL) PIPERAZIN 1 YL]BUTYL] 1,3 DIHYDRO 2H INDOL 2 ONE OXALATE; 3 ETHYL 3 [4 [4 (4 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO PYRIDIN 1 YL]BUTYL] 1,3 DIHYDRO 2H INDOL 2 ONE; 3 ETHYL 3 [4 [4 (4 FLUOROPHENYL) PIPERAZIN 1 YL]BUTYL] 1,3 DIHYDRO 2H INDOL 2 ONE; 3 ETHYL 3 [4 [4 (4 FLUOROPHENYL) PIPERIDIN 1 YL]BUTYL] 1,3 DIHYDRO 2H INDOL 2 ONE; 5 CHLORO 3 [4 [4 (3 CHLOROPHENYL) PIPERAZIN 1 YL]BUTYL] 3 ETHYL 6 FLUORO 1,3 DIHYDRO 2H INDOL 2 ONE; 5 FLUORO 3 [4 (4 PHENYL PIPERAZIN 1 IL)BUTYL] 1,3 DIHYDRO 2H INDOL 2 ONE; 5,7 DICHLORO 3 [4 [4 (4 CHLOROPHENYL) PIPERAZIN 1 YL]BUTYL] 3 ETHYL 1,3 DIHYDRO 2H INDOL 2 ONE; HALOGEN; HALOPHENYL 1,2,3,6 TETRAHYDROPYRIDINE; NITROGEN; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST;

ANIMAL CELL; ARTICLE; DRUG ACTIVITY; DRUG POTENCY; FEMALE; NONHUMAN; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TRANQUILIZING ACTIVITY;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SPECTROPHOTOMETRY, INFRARED;

EID: 43049113873     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070279v     Document Type: Article

References (55)

1. Hoyer, D.; Hannon, J. P.; Martin, G. R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol., Biochem. Behav. 2002, 71, 533-554.
2. 7. J. Med. Chem. 2003, 46, 2795-2810.
3. Roth, B. L.; Craigo, S. C.; Choudhary, M. S.; Uluer, A.; Monsma, F. J., Jr.; Shen, Y.; Meltzer, H. Y.; Sibley, D. R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharm. Exp. Ther. 1994, 268, 1403-1410.
4. 7 receptor regulation in the rat hypothalamus. Neuropsychopharmacology 1999, 21, 352-367.
5. 7 receptors. Br. J. Pharmacol. 1999, 127, 236-242.
6. 7 receptor antagonist. Br. J. Pharmacol. 2000, 130, 539-548.
7. 7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment. Mol. Pharmacol. 1995, 47, 99-103.
8. 7 receptor antagonist of potential clinical interest. CNS Drug Rev. 2002, 8, 90-100.
9. 7 receptor mediating smooth muscle relaxation in canine cerebral arteries. Br. J. Pharmacol. 1999, 127, 609-616.
10. 7 receptor involved in the pathogenesis and prophylactic treatment of migraine? Eur. J. Pharmacol. 2002, 439, 1-11.
11. 7 receptors mediate serotonergic effects on light-sensitive suprachiasmatic nucleus neurons. Brain Res. 1997, 755, 246-254.
12. 7 receptor antagonist, modulates REM sleep in rats. Br. J. Phannacol. 2003, 139, 705-714.
13. 7 antagonist: (R)-3-(2-(2-(4- methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl)phenol (SB-269970), J. Med. Chem. 2000, 43, 342-345.
14. 7 receptor antagonists. J. Med. Chem. 2001, 44, 1337-1340.
15. 7 receptor agonists and antagonists. J. Med. Chem. 2004, 47, 3927-3930.
16. 7 receptor antagonist with improved in vivo properties. Bioorg. Med. Chem. Lett. 2002, 12, 3341-3344.
17. 7 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 1055-1058.
18. 7 antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 4245-4248.
19. 7 receptor agents. J. Med. Chem. 2004, 47, 6616-6624.
20. 7 agonists. Bioorg. Med. Chem. Lett. 2003, 13, 269-271.
21. 7 receptor ligands. J. Med. Chem. 2003, 46, 646-649.
22. 7 receptor. Bioorg. Med. Chem. Lett. 2005, 15, 747-750.
23. Koyama, M.; Kikuchi, Ch.; Ushiroda, O.; Ando, T.; Nagaso, H.; Fuji, K.; Okuno, M.; Hiranuma, T. Preparation of tetrahydrobenzindole derivatives for the treatment or prevention of mental diseases. WO 9800400 (EP 937 715), 1997; Chem. Abstr. 1997, 128114961.
24. 7 receptor. J. Med. Chem. 1999, 42, 533-535.
25. 7 receptor. J. Med. Chem. 2002, 45, 2197-2206.
26. 7 receptor. Bioorg. Med. Chem. Lett. 2002, 12, 2549-2552.
27. 7 antagonists with increased in vitro metabolic stability. Bioorg. Med. Chem. Lett. 2003, 13, 61-64.
28. Volk, B.; Mezei, T.; Simig, G. Raney nickel-induced 3-alkylation of oxindole with alcohols and diols. Synthesis 2002, 595-597.
29. Volk, B.; Simig, G. New one-pot synthesis of 3-alkyl- and 3-(ω-hydroxyalkyl)oxindoles from isatins. Eur. J. Org. Chem. 2003, 3991-3996.
30. Porcs-Makkay, M.; Volk, B.; Kapiller-Dezsöfi, R.; Mezei, T.; Simig, G. New routes to oxindole derivatives. Monatsh. Chem. 2004, 135, 697-711.
31. This difficulty is investigated in detail in Gruda. I. Formation des dérivés N- et C-substitués au cours de l'alkylation de l'indol-2(3H)-one. Can. J. Chem. 1972, 50, 18-23.
32. Reisch, J.; Müller, M.; Labitzke, H. Synthesewege zu 3-substituierten Indol-2-onen Arch. Pharm. (Weinheim, Germany) 1984, 317, 639-646;
33. Chem. Abstr. 1984, 101, 130558e.
34. Kende, A. S.; Hodges, J. C. Regioselective C-3 alkylations of oxindole dianion. Synth. Commun. 1982, 12, 1-10.
35. Popp, F. D. The chemistry of isatin. In Advances in Heterocyclic Chemistry. Vol. 18; Katritzky, A. R., Boulton, A. J., Eds.; Academic Press: New York. 1975; pp 2-5.and references cited therein.
36. 7 receptors. J. Comput. Aided Mol. Des. 2001, 15, 883-909.
37. Vogel, J. R.; Beer, B.; Clody, D. E. A simple and reliable conflict procedure for testing antianxiety agents. Psychopharmacology (Berlin) 1971, 21, 1-7.
38. Costall, B.; Jones, B. J.; Kelly, M. E.; Naylor, R. J.; Tomkins, D. M. Exploration of mice in a black and white test box: validation as a model of anxiety. Pharm. Biochem. Behav. 1989, 32, 777-785.
39. 7 receptor ligands. Bioorg. Med. Chem. Lett. 2005, 15, 3753-3757, and references cited herein.
40. 1A functional characteristics. Bioorg. Med. Chem. 2005, 13, 2293-2303.
41. 7 receptor agents. 2. J. Med. Chem. 2007, 50, 4214-4221.
42. 7 receptor ligands. Bioorg. Med. Chem. Lett. 2006, 16, 1255-1258.
43. 2A receptor signaling modulates anxiety-like behaviors in mice. Science 2006, 313, 536-540.
44. 2A/2C agonist) in the four plate test. Psychopharmacology 2006, 183, 471-481.
45. 7 receptors. Eur. J. Pharmacol. 2004, 495, 97-102.
46. (a) Volk, B.; Barkóczy, J.; Simig, G.; Mezei, T.; Kapiller-Dezsöfi, R.; Gacsályi, I.; Pallagi, K.; Gigler, G.; Lévay, G.; Móriez, K.; Leveleki, C.; Sziray, N.; Szénási, G.; Egyed, A.; Hársing, L. G. Preparation of indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders. WO 2005108390, 2005; Chem. Abstr. 2005, 143, 477847.
47. 7 receptor active agents. WO 2005108388, 2005; Chem. Abstr. 2005, 143, 477850.
48. 7 receptor active agents for treating or preventing central nervous system or cardiovascular system disorders. WO 2005108363, 2005; Chem. Abstr. 2005, 143, 477984.
49. (d) Volk, B.; Barkóczy, J.; Simig, G.; Mezei, T.; Kapiller-Dezsöfi, R.; Gacsályi, I.; Pallagi, K.; Gigler, G.; Lévay, G.; Móricz, K.; Leveleki, C.; Sziray, N.; Szénási, G.; Egyed, A.; Hársing, L. G. Preparation of piperazine derivatives of alkyl oxindoles for treating or preventing central nervous system or cardiovascular disorders. WO 2005108364, 2005; Chem. Abstr. 143, 477985.
50. 1 receptors for use against central nervous system and other diseases. WO 2005109987, 2005; Chem. Abstr. 2005, 143, 477989.
51. 1A receptor affinity in the group of long-chain arylpiperazine ligands. Bioorg. Med. Chem. Lett. 2004, 14, 5863-5866.
52. 7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives. J. Med. Chem. 2003, 46, 5638-5650.
53. 7 antagonism. Bioorg. Med. Chem. Lett. 2000, 10, 1097-1100.
54. 1A receptors. J. Pharm. Pharmacol. 2004, 56, 247-255.
55. 3H]spiroperidol. Mol. Pharmacol. 1979, 16, 687-699.